Is Bydureon BCise FDA Approved?

DrugStatusIndex provides a clear, data-driven view of the regulatory status of medications, compounds, and related products. This page explains whether Bydureon BCise is FDA approved and how it is commonly categorized.

▤

Overview

Bydureon BCise is the brand name for exenatide extended-release, a once-weekly GLP-1 receptor agonist used to improve blood sugar control in patients with type 2 diabetes.

✓

FDA Status Details

Bydureon BCise is classified as FDA Approved. It was first approved by the FDA in October 2017 for treatment of type 2 diabetes and later expanded for pediatric patients ages 10 and older. :contentReference[oaicite:0]{index=0}

Approved Use

Bydureon BCise is approved as an adjunct to diet and exercise to improve glycemic control in adults and certain pediatric patients with type 2 diabetes. It is not approved for weight loss treatment. :contentReference[oaicite:1]{index=1}

⚗

Availability Update

Although FDA approved, AstraZeneca discontinued Bydureon BCise in the United States as a business decision rather than for safety or effectiveness concerns. :contentReference[oaicite:2]{index=2}

Bydureon BCise FDA Status

✓

FDA Approved

Bydureon BCise is listed as FDA Approved as a prescription medication for type 2 diabetes, though it has since been discontinued in the U.S. market. :contentReference[oaicite:3]{index=3}

Why People Search This

Users often search for Bydureon BCise to understand whether it is still approved, how it compares to Ozempic and other GLP-1 medications, and whether discontinued drugs remain FDA approved.

Disclaimer

This page is for informational purposes only and reflects publicly available regulatory data. It does not provide medical advice or treatment recommendations.

Search Another Drug or Compound

Use DrugStatusIndex to review public regulatory status information for medications, compounds, and related products.

Search the Index